Cancer: treatment hinges on regional coordination – waits of up to 13 months for a new therapy
Focus on disparities in access and the failure to utilise 3 billion from the Innovative Medicines Fund over nine years: Aiom oncologists highlight the need for equity for the 390,000 new cases each year
Key points
A three-day event dedicated to the theme of equity: this means making full use of the most innovative treatments, which in Italia are supported by a dedicated fund that is not currently being fully utilised, but also drastically reducing the time it takes for patients across the country to gain access, on an equal footing, to new treatments authorised for reimbursement by the Italian Medicines Agency (AIFA). These are the issues at the heart of the Italian Association of Medical Oncology (AIOM), which is meeting in Rome from today for its 28th National Congress. The data paint a picture that clearly leaves room for improvement and which, in fact, impacts the fairness of access to treatment for the 390,000 people who are diagnosed with the disease each year in the country and for the approximately 3.7 million people living with the disease. There are two figures to highlight in red: 400 days, which is the maximum waiting time for a patient (and their carer) to receive a new treatment; 3 billion euros, representing the resources left unused over nine years (2018–2025) from the innovative medicines fund, with an upward trend. Whilst 91 per cent of the resources were spent in 2018, by 2025 this figure had fallen to just 53 per cent.
The Aiom analysis
Most of the treatments included in the Fund are for cancer: they account for 31 of the 55 indications for 2025, amounting to 353 million euros, more than half of the total expenditure (700 million). Failure to utilise these resources may result in innovative cancer treatments being unavailable to patients, creating regional inequalities. The time between AIFA’s approval for reimbursement and the award of the procurement contract can vary from 100 to 400 days across different regions (the average time is 165 days). Among the causes are the regionalisation of care pathways, as well as the variety of procurement models and local organisational decisions, which contribute to creating inequalities in access.
On the other hand, the length of time a treatment remains in the Fund can also have an impact, according to Aiom. The maximum duration for which a treatment is recognised as innovative is three years, with no possibility of extension, even in the absence of more effective treatments. The under-utilisation of resources is leading to cuts to the Fund. The 2026 Budget Act has stipulated that, with effect from 2026, the Fund’s resources are to be reduced by 140 million euros annually. Aiom is calling for a new model of innovation governance, one that removes local bureaucratic and administrative barriers to the immediate availability of these therapies and which, in certain cases, allows therapies to remain in the Fund for up to five years.
“Innovation can only be fully realised if all citizens can benefit from it equally, regardless of where they live or receive treatment,” explains Massimo Di Maio, President of AIOM. “Italia was among the first countries in the world to establish a comprehensive regulatory framework for the assessment of innovative medicines. Recognition by AIFA that a treatment is fully innovative entails direct access to the Fund’s resources and automatic inclusion in regional formulary lists. In reality, however, medicines that should be immediately available to all patients are, in some cases, not accessible to everyone.”
Planning your shopping
The allocation of the Fund’s resources is linked to dispensing data in AIFA’s monitoring systems, but there may be delays in the activation of the registers. ‘There is still a limited frequency of reports from AIFA to the Regions,’ continues President Di Maio, ‘whilst, at regional and local level, the communication of monthly data on the Fund’s utilisation to hospital trusts is not sufficiently timely. These information gaps hinder effective planning of hospital expenditure and activities. Consequently, regional expenditure is not accurately tracked and reimbursed in a timely manner. Furthermore, some Regions, despite the publication in the Official Gazette of the AIFA decision establishing a medicine’s full innovative status, impose further obstacles; for example, they reduce the number of prescribing centres, introduce different procurement procedures for tenders and company authorisations, or centralise stages of the process.”

